Tag #Pharmaceutical Industry

dailymail.co.uk
🌐 85% Global Worthiness
News related image

Labour's AstraZeneca Snub Threatens UK Science Hub Ambitions

Labour's refusal to support AstraZeneca's £450 million Liverpool vaccine plant clashes with their science goals, contrasting with US government support and potentially driving investment away from the UK.

Progress

64% Bias Score

Decent Work and Economic Growth
abcnews.go.com
🌐 75% Global Worthiness
News related image

Walgreens Suspends Dividend After 90+ Years, Stock Plunges 11%

Walgreens Boots Alliance Inc. suspended its dividend after more than 90 years, causing an 11% stock drop in premarket trading due to financial challenges including legal issues, rising costs, and reduced consumer spending; the company plans to close 1200 stores.

Progress

40% Bias Score

Decent Work and Economic Growth
lentreprise.lexpress.fr
🌐 85% Global Worthiness
News related image

Europe's Slow Progress Towards Pharmaceutical Sovereignty

Europe's pharmaceutical supply chain is vulnerable due to reliance on distant countries for raw materials and production; this has led to shortages of essential medicines, prompting calls for higher drug prices and increased domestic production.

Progress

40% Bias Score

Good Health and Well-being
taz.de
🌐 85% Global Worthiness
News related image

Record Irish Tax Revenue: A Windfall Threatened by US Policies

Ireland's 2023 tax revenue hit a record \$108 billion, a 23% increase driven by Apple's \$11 billion tax payment and rising income tax. However, this prosperity is threatened by potential US tariffs and tax code changes.

Progress

48% Bias Score

Reduced Inequality
forbes.com
🌐 85% Global Worthiness
News related image

FTC Accuses PBMs of \$8.7 Billion in Price Gouging

The FTC released a report accusing the three largest Pharmacy Benefit Managers (PBMs)—OptumRx, Express Scripts, and CVS Caremark—of marking up specialty generic drug prices by over \$7.3 billion from 2017-2022, and an additional \$1.4 billion through spread pricing, ultimately increasing patient cos...

Progress

24% Bias Score

No Poverty
cnbc.com
🌐 85% Global Worthiness
News related image

Eli Lilly Stock Tumbles Despite Positive 2025 Outlook

Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...

Progress

40% Bias Score

Good Health and Well-being
zeit.de
🌐 85% Global Worthiness
News related image

US-EU Trade Conflict Threatens German Pharmaceutical Industry

A potential US-EU trade conflict under Donald Trump significantly threatens Germany's pharmaceutical industry, which exported \$26 billion worth of drugs to the US in 2023, making the US its most important export market and supplier of raw materials. This dependence raises concerns about potential d...

Progress

44% Bias Score

Good Health and Well-being
jpost.com
🌐 75% Global Worthiness
News related image

Teva Exceeds 2024 Expectations but 2025 Outlook Disappoints

Teva Pharmaceutical Industries reported exceeding 2024 financial results with $4.2 billion in Q4 revenue and $16.5 billion in full-year revenue; however, its share price fell almost 10% due to a less optimistic 2025 outlook of $16.8-17.4 billion in revenue and $2.35-2.65 non-GAAP EPS.

Progress

36% Bias Score

Good Health and Well-being
theglobeandmail.com
🌐 85% Global Worthiness
News related image

Canadian Court Certifies Class-Action Lawsuit Against Opioid Companies

A British Columbia Supreme Court judge certified a class-action lawsuit against over 40 opioid companies for allegedly over-promoting prescription opioid use, leading to substantial public health care costs; the B.C. government, joined by all other Canadian governments, alleges wrongful conduct and ...

Progress

44% Bias Score

Good Health and Well-being
theglobeandmail.com
🌐 75% Global Worthiness
News related image

Healthcare Sector Lags Despite Innovation, Poised for Growth

The healthcare sector, particularly biotech, is underperforming despite promising innovations due to investor apathy and post-pandemic market corrections; however, experts anticipate future growth fueled by technological advancements, demographic shifts, and potential deregulation.

Progress

56% Bias Score

Good Health and Well-being
bbc.com
🌐 85% Global Worthiness
News related image

Iran's Medicine Crisis: Price Hikes, Shortages, and Hospital Thefts

Due to reduced government subsidies, a rise in the dollar's exchange rate, and raw material shortages, medicine prices in Iran have sharply increased, causing shortages, hospital drug thefts, and endangering patients; the government's debt to the pharmaceutical industry and insurance companies furth...

Progress

40% Bias Score

Good Health and Well-being
nrc.nl
🌐 85% Global Worthiness
News related image

Galapagos Restructures, Splits into Two, Cuts 300 Jobs

Galapagos, a Dutch-Belgian biotech firm facing financial struggles after setbacks in US market approvals, is splitting into two entities: one focusing on oncology cell therapy, and SpinCo, receiving \u20ac2.45 billion for acquisitions, resulting in 300 job cuts and separation from a restrictive agre...

Progress

40% Bias Score

Good Health and Well-being